Our Team

Robert Cobuzzi, Jr., PhD

President, Chief Executive Officer and Board Member

Dr. Cobuzzi has served as President, Chief Executive Officer and Board Member since September 2020 and as a director since January 2020. He has over 25 years of cross-functional leadership experience in the pharmaceutical and biotechnology industries across the areas of Corporate Development, Research & Development, and Operations.

  • From 2005 until 2018 Dr. Cobuzzi held a variety of senior roles in Corporate Development, R&D and Operations at Endo International Plc, including most recently as President, Endo Ventures Limited in Dublin, Ireland from 2015 until 2018. Prior to Endo, he was with Adolor Corporation from 2001 until 2005. He began his career in 1995 at AstraMerck in clinical operations before joining Centocor (a subsidiary of Johnson & Johnson) in Worldwide Regulatory Affairs from 1999 to 2001. Dr. Cobuzzi currently serves as a Venture Partner for Sunstone Life Science Ventures and also is Chairman of Sunstone’s Business Development Board. He was previously a member of the U.S. Department of Commerce’s Industry Trade Advisory Committee on Chemicals, Pharmaceuticals, Health/Science Products and Services, and served as a board member for two development-stage medical device companies. Dr. Cobuzzi holds an AB in Biochemistry and Art History from Colby College and a PhD in Molecular and Cellular Biochemistry from Loyola University Chicago. He was a post-doctoral fellow in the Department of Experimental Therapeutics at the Roswell Park Cancer Institute in Buffalo, N.Y.

Christopher D. Galloway, MD

Chief Medical Officer

Dr. Galloway joined Diffusion as Chief Medical Officer as of October 2020. He is an Executive Physician with diverse Clinical and Pharmaceutical Industry experience. He has over 20 years of combined practice as an ER physician with industry leadership roles within Clinical Development & Operations and Medical Affairs across multiple therapeutic areas and stages of development.

  • Dr. Galloway joins Diffusion from La Jolla Pharmaceuticals, where he has served as senior medical director – medical affairs in critical care since August 2018. Among his duties at La Jolla, he chaired and oversaw investigator-initiated and collaborative research programs. Prior to La Jolla, he was medical director for global clinical development at the immuno-oncology company Rakuten Medical from 2016 to 2018. At Rakuten, he was involved in protocol and synopsis design, and trial execution from Phase 1 through Phase 3 in multiple indications. Previously, he was a medical affairs director for Merck focused on immunotherapy, allergy and asthma, and served as medical director and principal investigator for DaVita Clinical Research, a contract research organization. Dr. Galloway received his MD degree from the University of Texas Medical Branch at Galveston, and was a resident in emergency medicine at Carolinas Medical Center in Charlotte, NC. He received a BA in biology from the University of Texas at Austin, and is licensed to practice medicine in Colorado and Texas. Dr. Galloway is a Diplomate of the American Board of Emergency Medicine and a Diplomate with the American Board of Quality Assurance and Utilization Review Physicians.

Bill Hornung

Chief Financial Officer

Mr. Hornung has served as the Chief Financial Officer of Diffusion Pharmaceuticals Inc. since September 2018 and prior to that served as our Chief Business Officer from August 2017 to September 2018. Mr. Hornung has over twenty years of experience in the biopharmaceutical industry.

  • As CBO of the Company, Mr. Hornung has responsibility for implementing the Company’s overall business development strategy and will manage investor, bank, and analyst relationships. Prior to joining Diffusion Pharmaceuticals Inc., Mr. Hornung held the position of Chief Financial Officer at Contravir Pharmaceuticals, Inc. Prior to Contravir, Mr. Hornung held positions of increasing responsibility with PTC Therapeutics Inc., most recently serving as Vice President of Finance. During his tenure at PTC Therapeutics (December 2002 through March 2014), Mr. Hornung oversaw the IPO process in which PTC became a publicly traded company. Mr. Hornung also held positions of increasing responsibility with Elan Pharmaceuticals (formerly The Liposome Company) from 1998 through 2002. At Liposome and Elan, he was responsible for strategic planning and operations of the company’s UK-based European headquarters. Earlier in his career, Mr. Hornung worked for a clinical research organization where he was responsible for project management and all financial aspects of the company. Mr. Hornung holds a Bachelor of Science in Accounting from the William Paterson State University of New Jersey. He lives in Virginia with his wife Kristin.

Raven Jaeger

Chief Regulatory Officer

Mrs. Jaeger joined Diffusion as Chief Regulatory Officer in May 2022. She is an Executive Regulator with over 20 years of experience within the pharmaceutical and biotechnology industries where she managed unique and complex global development programs focused on the treatment of rare diseases across multiple therapeutic areas, including oncology, neurology, metabolic and autoimmune diseases, vaccines, cardiology, and various liver diseases, for drugs and biologics under investigational and commercialization phases of development.

  • As the Chief Regulator Officer of the company, Mrs. Jaeger is responsible for the development and execution of the regulatory strategy for the program portfolio.  Prior to joining Diffusion, Mrs. Jaeger was the Senior Vice President of Regulatory Affairs at BridgeBio Pharma, Inc. During her time there, she successfully built and led a regulatory affairs team responsible for global regulatory strategy and operations for multiple development programs within several affiliate companies, whereby she led her team to gaining the first US FDA regulatory approval for the company. From 2008 to 2018, Mrs. Jaeger was the Head of Regulatory Affairs at Leadiant Biosciences, Inc. and supported multiple programs at ICON Development Solutions and at Nabi Biopharmaceuticals, Inc. She brings with her experience in obtaining multiple drug and biologic marketing authorization approvals in the rare disease space, two of which resulted in the granting of a rare pediatric disease voucher, and she was integral in obtaining other key regulatory designations including Orphan Drug Designation, Fast Track Designation, Breakthrough Therapy Designation, and Rare Pediatric Disease Designation. Mrs. Jaeger began her career at the National Institute of Mental Health and the National Institutes of Health Center for Scientific Review. She holds an M.S. in biotechnology management from the University of Maryland and a B.S. in natural sciences area with an emphasis in biology and biophysics from The Johns Hopkins University

William Elder, JD

General Counsel

Bill Elder has served as General Counsel since September 2020. He is an attorney with nearly a decade of experience advising public and private companies in a variety of corporate, securities, governance, regulatory, and general commercial matters. He also previously served as a consultant to Diffusion from July 2020 to September 2020.

  • Prior to joining Diffusion, Bill spent eight years as an associate at the law firm of Dechert LLP, counseling clients in a broad range of transactions and other matters, including serving as outside counsel to Diffusion in connection with the Company’s reverse merger in 2016 and several subsequent financings. Bill received a JD from the University of Pennsylvania School in Law, a MSF (Master of Science in Finance) from Villanova University, and a BA in Economics from Tufts University. Bill is licensed to practice law in the Commonwealth of Pennsylvania, where he lives with his dog, Stamos.

Jon Adams

Clinical Trial Associate

Jon Adams has worked as a Clinical Trial Associate for Diffusion since July 2021. He began working for Diffusion as an Analyst in August 2017.

  • Prior to joining Diffusion, Jon received a BA in Business Administration with a Minor in Chemistry at Lynchburg College, now University of Lynchburg.

Kelly Arscott

Director of Clinical Operations

Kelly Arscott has served as Director of Clinical Operations since June 2021. She has more then 15 years of Research & Development and Operations experience in the academic, pharmaceutical and biotech space.

  • Kelly joins Diffusion from Trevena, Inc. where she served as Director of Clinical Operations and Alliance Manager. In her five years with the company, she supported the clinical program of their primary asset, OLINVYK™, from clinical development through to approval and commercialization. She also initiated the clinical programs for several of the company’s early pipeline assets and managed the relationships with their Chinese and South Korean licensing partners. Prior to this role, Kelly held a number of clinical research positions at ACI Clinical, the Philadelphia VA Medical Center, University of Pennsylvania and University of Virginia. Kelly received a BA in Psychology from Gettysburg College.

Suzanne Cassidy

Senior Director, Head of Quality Assurance

Suzanne Cassidy has served as Senior Director and Head of Quality Management since March 2021.  Suzanne has over 20 years of Quality Assurance leadership experience in the pharmaceutical and biotechnology industries spanning the areas of Pre-Clinical, Clinical, Manufacturing and Pharmacovigilance.

  • Suzanne joined Diffusion from eResearch Technologies where she served as Senior Director and Head of Operational Quality Assurance.  Among her duties were the establishment and maintenance of all operational aspects of the GxP Quality Management System.  Ms. Cassidy was responsible for overall management the execution of the Internal/Vendor Audit Program, External Audit hosting, Designated Complaint Unit, GCP Compliance functions and regulatory inspection management.   Prior to this role, Ms. Cassidy served in increasing leadership positions with Quality Assurance at Morphotek, including acting Head of R&D Quality Assurance for GLP & GCP operations.  Ms. Cassidy received a Bachelor of Science in Biology from St. Joseph’s University in Philadelphia.  She lives in Pennsylvania with her husband, Stephen.

Ted Crane

Senior Director of Financial Planning & Analysis

Ted Crane joined Diffusion as Senior Director of Financial Planning & Analysis in June of 2021. He has over 20 years of experience in senior finance roles across various industries and eight years of experience in pharmaceutical and biopharmaceutical companies.

  • Ted joined Diffusion from Lannett, a generic pharmaceutical company, where he served as Director of Financial Planning & Analysis. While at Lannett, he worked on the acquisition and integration of Kremers Urban, assisted in various debt and equity capital transactions, and supported the Investor Relations activity in addition to leading the FP&A organization. Prior to Lannett, Ted worked as a contractor with various companies, such as CSL Behring, as financial support for CSL’s commercial organization. He began his career with Lockheed Martin as a member of their independent cost estimating (ICE) group before joining various companies such as Intuit, Medscape and The Corporate Marketplace (TCMPi) in financial leadership positions. Ted holds a Bachelor of Science in Accounting from the University of Rhode Island and an MBA from Babson’s Olin Graduate School of Business where he graduated Magna Cum Laude.

Laura Fowler, SHRM-SCP

Executive Administrator

Laura joined the Diffusion team as Executive Administrator in June 2022. She brings more than 15 years of organizational administration and project management experience from various industries, including biotech, financial services, and insurance.

  • Laura earned her SHRM-SCP credentials from the Society for Human Resource Management in 2022. She is based in the suburbs of Philadelphia, PA where she lives with her feline friends, Ivy and Luna.

Jennifer Llewelyn, PhD

Sr. Director, Head of CMC

Dr. Llewelyn joined Diffusion as Senior Director and Head of CMC in September 2021. Jennifer brings over twenty years of technical and leadership experience from her roles in Research & Development and Operations.

  • Jennifer joined Diffusion from Incyte Corporation where she served as Senior Director of Analytical Development. While at Incyte, Dr. Llewelyn had the privilege of providing technical and leadership oversight to bring medicines to patients; from early phase clinical studies through to approval for commercialization, both in the US and globally. Dr. Llewelyn began her career at AstraZeneca in Analytical Research and Development where she gained extensive experience in drug development. Dr. Llewelyn received her B.S. in chemistry from Lindenwood College and a Ph.D. in Analytical Chemistry from The Florida State University.

Kim Ramos

Senior Data Manager

Kim joined Diffusion as Senior Data Manager in July 2021. She has nearly a decade of clinical research experience at the site, vendor and sponsor levels.

  • Prior to joining Diffusion, she served as Senior Data Manager at Palvella Therapeutics, where she led data management for three clinical studies through critical program milestones. Preceding Palvella, she held data management positions of increasing responsibility at Intact Vascular & Vesper Medical, and Trevena, Inc. During her tenure at Trevena, Kim managed study data (Phase I-III) and documentation for their OLINVYK™ program in preparation for FDA New Drug Application submission and served as a triage member at the subsequent FDA Advisory Committee meeting. Her previous therapeutic experience includes stroke, peripheral artery disease, pain and rare disease. She received her undergraduate degree from West Chester University and her MS from Seton Hall University.

Rochelle Rivera

Staff Accountant

Rochelle Rivera has worked as a Staff Accountant for Diffusion since September 2021.

  • Before joining Diffusion, Rochelle was a staff accountant and accounting intern at various organizations throughout Philadelphia, PA. Rochelle received a BBA in Accounting with a concentration in Data Analytics from Temple University.

Back to top